Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nemifitide. Innapharma.

Jasper Dingemanse1

  • 1Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil, Switzerland. Jasper.Dingemanse@actelion.com

Current Opinion in Investigational Drugs (London, England : 2000)
|November 19, 2003
PubMed
Summary

Nemifitide, a novel peptide, is being developed for depression treatment. Phase II trials were completed by June 2001, with Phase III trials anticipated for late 2003.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function.

Journal of psychopharmacology (Oxford, England)·2024
Same author

Multiple-dose pharmacokinetics of cenerimod and the effect of charcoal on its elimination.

Journal of clinical pharmacology·2024
Same author

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.

Clinical and translational science·2024
Same author

The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant.

Clinical and translational science·2024
Same author

Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A.

Journal of clinical pharmacology·2024
Same author

Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women.

Journal of clinical pharmacology·2024

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Trials

Background:

  • Depression is a prevalent mood disorder with significant unmet treatment needs.
  • Current antidepressant therapies have limitations in efficacy and side effect profiles.
  • Novel therapeutic targets and agents are crucial for improving depression management.

Purpose of the Study:

  • To evaluate the efficacy and safety of nemifitide as a potential treatment for depression.
  • To advance the development of nemifitide through clinical trial phases.
  • To explore the therapeutic potential of peptide-based interventions in psychiatric disorders.

Main Methods:

  • Phase II clinical trial involving individuals with moderate to severe depression.
  • Assessment of treatment response and adverse events.
  • Data analysis to determine preliminary efficacy and safety signals.

Main Results:

  • Phase II trial of nemifitide in moderate to severely depressed individuals completed by June 2001.
  • Innapharma anticipated commencement of Phase III trials in late 2003.
  • Preliminary data from Phase II informed the progression to Phase III development.

Conclusions:

  • Nemifitide demonstrated potential as a novel therapeutic agent for depression.
  • Successful completion of Phase II trials paved the way for larger-scale Phase III investigations.
  • The development of nemifitide represents a promising advancement in the pharmacological treatment of depression.

Related Experiment Videos